- Home
- REGN vs GM Comparison
REGN vs GM Comparison
Compare REGN & GM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- GM
- Stock Information
- Founded
- REGN 1988
- GM 1908
- Country
- REGN United States
- GM United States
- Employees
- REGN N/A
- GM N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- GM Auto Manufacturing
- Sector
- REGN Health Care
- GM Consumer Discretionary
- Exchange
- REGN Nasdaq
- GM Nasdaq
- Market Cap
- REGN 59.5B
- GM 50.5B
- IPO Year
- REGN 1991
- GM N/A
- Fundamental
- Price
- REGN $589.48
- GM $58.38
- Analyst Decision
- REGN Buy
- GM Buy
- Analyst Count
- REGN 22
- GM 17
- Target Price
- REGN $806.32
- GM $56.24
- AVG Volume (30 Days)
- REGN 1.0M
- GM 7.1M
- Earning Date
- REGN 08-01-2025
- GM 07-22-2025
- Dividend Yield
- REGN 0.60%
- GM 1.03%
- EPS Growth
- REGN 5.03
- GM N/A
- EPS
- REGN 39.67
- GM 6.24
- Revenue
- REGN $14,214,200,000.00
- GM $187,600,000,000.00
- Revenue This Year
- REGN N/A
- GM N/A
- Revenue Next Year
- REGN $6.65
- GM N/A
- P/E Ratio
- REGN $14.86
- GM $9.36
- Revenue Growth
- REGN 5.38
- GM 5.34
- 52 Week Low
- REGN $476.49
- GM $41.60
- 52 Week High
- REGN $1,211.20
- GM $61.24
- Technical
- Relative Strength Index (RSI)
- REGN 60.67
- GM 71.95
- Support Level
- REGN $570.39
- GM $55.09
- Resistance Level
- REGN $585.00
- GM $57.41
- Average True Range (ATR)
- REGN 16.72
- GM 1.10
- MACD
- REGN 2.93
- GM 0.30
- Stochastic Oscillator
- REGN 68.39
- GM 93.95
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About GM General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under three segments: GM North America, GM International, and GM Financial. The United States now has four brands instead of eight under old GM. The company regained its US market share leadership in 2022, after losing it to Toyota due to the chip shortage in 2021. 2024's share was 17.0%. The Cruise autonomous vehicle arm, which GM now owns outright, previously operated driverless geofenced AV robotaxi services in San Francisco and other cities, but after a 2023 accident, GM decided that it will focus on personal AVs. GM Financial became the company's captive finance arm in 2010 via the purchase of AmeriCredit.